Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Shares Outstanding (2016 - 2025)

Lineage Cell Therapeutics' Shares Outstanding history spans 16 years, with the latest figure at $243.1 million for Q4 2025.

  • For Q4 2025, Shares Outstanding rose 10.3% year-over-year to $243.1 million; the TTM value through Dec 2025 reached $243.1 million, up 10.3%, while the annual FY2025 figure was $243.1 million, 10.3% up from the prior year.
  • Shares Outstanding reached $243.1 million in Q4 2025 per LCTX's latest filing, up from $230.3 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $243.1 million in Q4 2025 to a low of $162.1 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $187.9 million, with a median of $174.7 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding: increased 0.26% in 2023, then increased 25.96% in 2024.
  • A 5-year view of Shares Outstanding shows it stood at $169.5 million in 2021, then increased by 0.36% to $170.1 million in 2022, then increased by 2.88% to $175.0 million in 2023, then rose by 25.96% to $220.4 million in 2024, then rose by 10.3% to $243.1 million in 2025.
  • Per Business Quant, the three most recent readings for LCTX's Shares Outstanding are $243.1 million (Q4 2025), $230.3 million (Q3 2025), and $228.4 million (Q2 2025).